At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetesRUTHERFORD, N.J., Jan. 29, 2025 ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design ...